Stemline Therapeutics

Stemline Therapeutics

NY - New York
Biotechnology2 H-1B visas (FY2023)
WebsiteLinkedInCareers Page

Focus: Cancer Stem Cells

Stemline Therapeutics is a life sciences company focused on Cancer Stem Cells.

OncologyCell Therapy
Employees
5000+
Open Jobs
0

Products & Portfolio (2)

ELZONRIS
tagraxofusp
Peak
INJECTION · SOLUTION
CD123 Interactions
blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adultsolder ()
2018
30
ORSERDU
elacestrant
Peak
ORAL · TABLET
Estrogen Receptor Antagonists
2023
0

Pipeline & Clinical Trials

N/A
Clinical Trials (1)
NCT05954780Selinexor (Nexpovio®) (SVd) in Patients With Relapsed or Refractory Multiple Myeloma
N/A
Phase 1
Clinical Trials (1)
NCT05382936Study of the PI3K Inhibitor SL-901 in Patients With Advanced Solid Tumors
Phase 1
Phase 1
Clinical Trials (1)
NCT03088527Phase 1, First-in-Human Study of RAD140 in Postmenopausal Women With Breast Cancer
Phase 1
Phase 1
Clinical Trials (1)
NCT02650817Phase IB Study to Evaluate RAD1901 on the Availability of Estrogen Receptor Binding Sites in Metastatic Breast Cancer
Phase 1
Phase 1
Clinical Trials (1)
NCT02338349A Phase I, Multicenter, Open-Label, Multi-Part, Dose-escalation Study of RAD1901 in Postmenopausal Women With Advanced Estrogen Receptor Positive and HER2-Negative Breast Cancer
Phase 1
Phase 1
Clinical Trials (1)
NCT03113643SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Phase 1
Phase 1
Clinical Trials (1)
NCT02667873A Trial of a Novel XPO1 Inhibitor in Participants With Advanced Solid Tumors
Phase 1
Phase 1
Clinical Trials (1)
NCT06638307A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer
Phase 1
Elacestrant dihydrochloride
Hepatic Impairment
Phase 1
Clinical Trials (1)
NCT06126575A PK Study Testing Single Oral Dose of Elacestrant in Subjects With Normal or Severely Impaired Hepatic Function
Phase 1
Phase 1
Clinical Trials (1)
NCT05720988Tagraxofusp to Eradicate Measurable Residual Disease in Patients With Acute Myeloid Leukemia
Phase 1
Phase 1
Clinical Trials (1)
NCT07226427A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer
Phase 1
Phase 1/2
Clinical Trials (1)
NCT07148180A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
Phase 1/2
Phase 1/2
Clinical Trials (1)
NCT06561152Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AML
Phase 1/2
SL-401 7 µg/kg/day
Multiple Myeloma
Phase 1/2
Clinical Trials (1)
NCT02661022SL-401 in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma
Phase 1/2
Elacestrant
Breast Neoplasms
Phase 1/2
Clinical Trials (1)
NCT05386108Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
Phase 1/2
Phase 1/2
Clinical Trials (1)
NCT07198724ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer
Phase 1/2
Tagraxofusp Injection
Myelofibrosis
Phase 1/2
Clinical Trials (1)
NCT02268253Tagraxofusp (SL-401) in Participants With Chronic Myelomonocytic Leukemia (CMML) and Myelofibrosis (MF)
Phase 1/2
Phase 1/2
Clinical Trials (1)
NCT02113982Tagraxofusp in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia
Phase 1/2
Tagraxofusp-erzs
Acute Myeloid Leukemia
Phase 1/2
Clinical Trials (1)
NCT02270463SL-401 as Consolidation Therapy in Patients With Adverse Risk Acute Myeloid Leukemia in First Complete Remission
Phase 1/2
SL-701; poly-ICLC
Adult Brain Glioblastoma
Phase 1/2
Clinical Trials (1)
NCT02078648Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme
Phase 1/2
Elacestrant
Breast Cancer
Phase 1/2
Clinical Trials (1)
NCT05563220Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer
Phase 1/2
Phase 2
Clinical Trials (1)
NCT05596409ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer Study
Phase 2
Phase 2
Clinical Trials (1)
NCT06201234Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer
Phase 2
Phase 2
Clinical Trials (1)
NCT05442216Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents
Phase 2
Phase 2
Clinical Trials (1)
NCT06923527Circulating Tumor DNA
Phase 2
Phase 2
Clinical Trials (1)
NCT07007052Phase II Study Evaluating the Efficacy and Safety of the Combination of Tagraxofusp and Venetoclax in Treatment-naive Blastic Plasmacytoid Dendritic Cell Neoplasm Patients
Phase 2
Phase 2
Clinical Trials (1)
NCT06456463A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy
Phase 2
Phase 2
Clinical Trials (1)
NCT07222215PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)
Phase 2
Elacestrant
Breast Cancer
Phase 3
Clinical Trials (2)
NCT06492616A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Phase 3
NCT07467772Ph 2 Elacestrant in ER Positive Uterine Sarcomas
Phase 2
Elacestrant
Breast Cancer
Phase 3
Clinical Trials (1)
NCT03778931Phase 3 Trial of Elacestrant Versus Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
Phase 3
Phase 3
Clinical Trials (1)
NCT06382948Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.
Phase 3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts
Portfolio: 2 approved products, 32 clinical trials
Top TAs: Oncology
H-1B (2023): 2 approvals
Portfolio Health
Peak2 (100%)
2 total products
Therapeutic Area Focus
Oncology
2 marketed1 pipeline
Marketed
Pipeline

Visa Sponsorship

Sponsors Work Visas
H-1B Petitions (FY2023)
2
Approved
0
Denied
100%
Rate

Source: USCIS H-1B Employer Data Hub